Precision Biologics, Inc. and National Cancer Institute Collaborators Deliver Poster Presentation at the ASCO Annual Meeting June 5, 2022
Precision Biologics, Inc. and our collaborators at the NCI deliver a poster presentation at the...
05Jun
07Apr
Dr. Philip M. Arlen provides perspective on the role of biomarkers for cancer immunotherapy at Oxford Global’s 2021 Biomarkers UK Conference
Dr. Philip M. Arlen provides perspective on the role of biomarkers for cancer immunotherapy at...
22Mar
Precision Biologics, Inc. Announces Issuance of U.S. Patent: “MONOCLONAL ANTIBODY NEO-201 FOR THE TREATMENT OF HUMAN CARCINOMAS”
Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announces that the U.S....
09Mar
Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics, San Diego, March 9, 2022
Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics 2022, San...
28Jan
Precision Biologics, Inc. appoints Dr. Joyson Karakunnel to the Board of Directors
Dr. Joyson Karakunnel joins the Board of Directors of Precision Biologics, Inc. as its newest...
11Nov
Precision Biologics to Deliver two Poster Presentations on our Clinical and Scientific Programs at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting at the Walter E Washington Convention Center, Washington DC Nov 12-13, 2021
November 12th: poster number 883 (12:40–2:10 p.m. and 7–8:30 p.m.) Title: An anti-carcinoma monoclonal antibody (mAb)...
08Nov
Dr. Philip M. Arlen gives scientific presentation at Biomarkers UK: In-Person, November 8, 2021, Manchester, UK
Dr. Philip M. Arlen gives scientific presentation at Biomarkers UK: In-Person, Day 1 – November...
29Oct
Phase II Clinical Trial NEO-201 in Combination with Pembrolizumab Detailed Study Information
The Phase 2 Clinical Trial with a safety lead in, combining Precision Biologics monoclonal antibody...
28Oct
Precision Biologics to Deliver two Oral Presentations on our Clinical and Scientific Programs at 6th Annual Neoantigen Based Therapies Summit, October 26-28th, Digital Event
Dr Massimo Fantini, Director of Research is Presenting the following Talk entitled : “Stability Tests...
14Oct
Precision Biologics Commences Phase 2 Clinical Trial using NEO-201 and Pembrolizumab as a 2nd line Therapy in Patients with Solid Tumors
Precision Biologics announces that a Phase 2 Clinical Trial, combining NEO-201 with Pembrolizumab, is recruiting...